PDP Pediapharm

Pediapharm Inc. ("Pediapharm" or the "Corporation") (TSX VENTURE:PDP) announces
that its Board of Directors has approved the grant of 3,810,000 stock options to
certain directors, officers and employees of the Corporation, subject to
regulatory and TSX Venture Exchange approval. The options were issued with an
exercise price of $0.46 per share and have a term of ten (10) years. In
addition, the options have varied vesting provisions such that they vest either
over three (3) or four (4) years. 


About Pediapharm 

Pediapharm is the only Canadian specialty pharmaceutical company, dedicated to
serving the needs of the pediatric community. Its mission is to bring to the
Canadian market the latest innovative pediatric products with the objective to
improve the health and the well-being of children in Canada. Since its debut in
2008, Pediapharm has entered into numerous commercial agreements with partners
from Canada and other countries around the world. The company's innovative
product portfolio includes NYDA(R); a breakthrough treatment for head lice;
EpiCeram(R) a non-steroid emulsion for eczema; KoolEffect(TM) which reduces the
symptoms of fever; and VapoLyptus(TM); a soothing vapour patch of Eucalyptus and
Camphor)  


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release. 


This press release shall not constitute an offer to sell or the solicitation of
an offer to buy any securities, nor shall there be any sale of securities in any
state in the United States in which such offer, solicitation or sale would be
unlawful. The securities referred to herein have not been and will not be
registered under the United States Securities Act of 1933, as amended, and may
not be offered or sold in the United States absent registration or an applicable
exemption from registration requirements.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Sylvain Chretien, President, Director
Pediapharm Inc.
514-762-2026 ext. 201
sylvain.chretien@pedia-pharm.com


Roland Boivin, CFO
Pediapharm Inc.
514-762-2026 ext. 202
roland.boivin@pedia-pharm.com

Pediapharm Inc. (TSXV:PDP)
Historical Stock Chart
Von Mai 2024 bis Jun 2024

Pediapharm Inc. (TSXV:PDP)
Historical Stock Chart
Von Jun 2023 bis Jun 2024